FindTrial
Sign In

To evaluate the effect of addition of kappa agonist to levobupivacaine in supraclavicular brachial plexus block on post op analgesia in the form of requirement of tramadol as recue analgesia in the postoperative period

Comparative study to evaluate the addition of nalbuphine and butorphanol as adjuvant to levobupivacaine for postoperative analgesia in supraclavicular brachial plexus block: A placebo controlled study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029863
Enrollment
120
Registered
2020-12-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Supraclavicular brachial plexus block in upper limb surgeries: to evaluate the effect of addition of nalbuphine and butorphanol to levobupivacaine in supraclavicular brachial plexus blo

Sponsors

SGRDIMSAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade I and II weight 40- 80kg surgeries of upper limb

Exclusion criteria

Exclusion criteria: patientâ??s refusal to participate in the study -Contraindications to regional anesthesia such as local infections Coagulation disorders -History of opioid dependence

Design outcomes

Primary

MeasureTime frame
to evaluate the effect of addition of nalbuphine or butorphanol to 0.5 % levobupivacaine on tramadol requirement postopTimepoint: to evaluate the effect of addition of nalbuphine or butorphanol to 0.5 % levobupivacaine on tramadol requirement postop onset of motor and sensory block will be done every minute after 10 minutes of injection until block has been established sparing of dermatomes will be noted duration od sensory and motor block will be recorded duration of analgesia is from onset of block to vas more than 40 will be noted postop analgesia will be noted at regular intervals till 24 hours—

Secondary

MeasureTime frame
procedure and drug related complicationsTimepoint: intraop and postop till 24 hours—

Countries

India

Contacts

Public ContactDr Ruchi Gupta

Sri Guru Ramdas Institute of Medical Sceinces and Research

gaganjotkaur84@gmail.com8198014504

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026